Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer (Q24193790)

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

The Intergroup Rhabdomyosarcoma Study-I. A final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Response to combination therapy after relapse in childhood acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Liver function studies in children with acute lymphocytic leukemia after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Prognostic factors for favorable outcome in disseminated germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Late effects of treatment for Wilms' tumor. A report from the National Wilms' Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Cardiac risk after mediastinal irradiation for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

[The COALL-85 cooperative study for risk patients with acute lymphatic leukemia: initial results]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Intraoperative spillage of favorable histology wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Multimodality treatment of osteosarcoma: radiation in a high-risk cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Local control of parameningeal rhabdomyosarcoma: outcomes in non-complete responders to chemoradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): Addition of an anthracycline to vincristine and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Brain metastases and testicular tumors: long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle L

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Results of children with renal tumors treated in the Austrian–Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93-01/GPOH trial in Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Current and emerging chemotherapy treatment strategies for Wilms tumor in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Statistical considerations in the intent-to-treat principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

A clinicopathologic analysis of adriamycin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Biology and treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Anthracyclines versus no anthracyclines for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

Long-term cause-specific mortality among survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

The treatment of Wilms' Tumor: Results of the second national Wilms' Tumor study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Rhabdomyosarcoma of the ear in childhood. A report from the intergroup rhabdomyosarcoma study-I

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Salvage chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: Experience by the Italian association of pediatric hematology and oncology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Analysis of clinical trials by treatment actually received: is it really an option?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

An update of Scandinavian studies of osteosarcoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL)--a single-institution study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

[Therapy results of the British ET-1 study for Ewing's sarcoma]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Mesenchymoma of the liver in childhood: five-year survival after combined-modality treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Local control in synchronous bilateral Wilms tumor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

[Aggressive cytostatic treatment of osteogenic sarcoma in childhood (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

The role of maintenance therapy in disseminated testicular cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Reduced therapy for Wilms' tumor: analysis of treatment results from a single institution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Acute toxicities associated with radiation in the second National Wilms' Tumor Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: a report of the Intergroup Rhabdomyosarcoma Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

The Third Intergroup Rhabdomyosarcoma Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Intensifying daunorubicin in induction for patients with core binding factor leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021

Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006647.PUB4

7 January 2021